SRRKNMSHealthcare·Biotechnology#46 in industry

Scholar Rock Holding Corporation

Reports in 10d· 2026-05-07

+5.2% · 90d

$46.29

-0.19 (-0.41%)

After-Hours $46.29(+0.00)

News

(2)

April 2026

Apr 22, 20265 days agoARSHealthcare

Insufficient information provided to write an editorial headline. Please submit the full summary of the SEC filing

SRRKScholar Rock Holding Corp

I need the actual content of the SEC filing to provide the comprehensive summary. The provided document structure only contains metadata (`<PDF></PDF>` with no content) and does not include the text or PDF itself. Please provide the full filing document, and I will execute the detailed, expert ana

Read summaryView on SEC EDGAR

Apr 22, 20265 days agoDEF 14AHealthcare

Scholar Rock files proxy statement for 2026 annual governance shareholder votes

SRRKScholar Rock Holding Corp

# 🧾 What This Document Is 📜 This document is a Definitive Proxy Statement for Scholar Rock Holding Corporation's 2026 Annual Meeting of Stockholders. In simple terms, this document is a detailed information packet mailed out to shareholders before the annual meeting. It explains what matters must

Read summaryView on SEC EDGAR

Key Data

Market Cap$5.52B

Open$46.48

Prev Close$46.48

Day Range$45.72 – $47.06

52W Range$27.07 – $51.63

Volume1,245,776

P/E (TTM)—

EPS$-3.29

Dividend Yield—

Beta0.69

Price Target$57.73(+24.7%)

Next Earnings2026-05-07(10d)

Analyst Ratings

Strong Buy17 analysts

Buy 17Hold 0Sell 0

About

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on improving the lives of children and adults with spinal muscular atrophy (SMA) and other rare, severe, and debilitating neuromuscular diseases. The company's novel understanding of the molecular mechanisms of growth factor activation within the transforming growth factor beta (TGFß) superfamily has enabled the development of a proprietary platform. This platform is used for the development of monoclonal antibodies that locally and selectively target the precursor, or latent, forms of growth factors. The company is developing Apitegromab, an inhibitor of the activation of myostatin, which is in a Phase 2 clinical trial for the treatment of SMA and facioscapulohumeral muscular dystrophy (FSHD). Additionally, SRK-439, an anti-pro/latent myostatin antibody, is in a Phase 1 clinical trial for the treatment of patients with rare, severe, and debilitating neuromuscular diseases. SRK-181 is a Phase 2-ready investigational inhibitor of latent TGFß1 for the treatment of patients with solid tumors that are resistant to anti-PD-(L)1 antibody therapies. The company also offers products in pre-clinical development, including SRK-373, a selective inhibitor of the latent TGFß1 isoform with selective activity in the fibrotic extracellular matrix, for the treatment of fibrotic diseases, and SRK-256, an inhibitor of RGMc, or hemojuvelin, for the treatment of iron-restricted anemias. Scholar Rock Holding Corporation is also developing a pipeline that includes programs for the treatment of patients with rare, severe, and debilitating neuromuscular diseases. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.

Healthcare · Biotechnology

289 employees

www.scholarrock.com